Contact
searchSearch
HMP Global
Login

Ovarian Cancer Resource Center

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
From Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024
Emry Lloyd
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
Stephanie Holland
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
From Oncology
Research Reports
Treatment Duration, Adherence, Interruptions, and Discontinuations Associated With Maintenance Regimens for Recurrent Ovarian Cancer
06/05/2023
Scott H. Bunner, MPH; Allison M. Saiz, MD; Nicole M. Engel-Nitz, PhD; Emma L. Barber, MD; Katrine L. Wallace, PhD
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and colleagues investigate current and real-world practice patterns for patients receiving maintenance therapy for recurrent ovarian cancer after second-line chemotherapy.
Emma L. Barber, MD, and...
06/05/2023
Journal of Clinical Pathways
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022
Yvette C. Terrie, BS Pharm, RPh
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022
Yvette C. Terrie, BS Pharm, RPh
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways

Expert Insights

Winston Wong, PharmD
Videos
Pathways Disruptors in Ovarian Cancer
06/22/2022
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly...
Winston Wong, PharmD, discusses...
06/22/2022
Journal of Clinical Pathways
Eloise Chapman-Davis, MD
Videos
Identifying Disparities in Genetic Testing Among Patients With Ovarian Cancer
06/14/2022
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD, discusses her research on existing disparities in genetic counseling in ovarian cancer, finding that less than half of patients with newly diagnosed breast or ovarian cancer receive germline testing, despite NCCN...
Eloise Chapman-Davis, MD,...
06/14/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD, GlaxoSmithKline
Videos
Real-World Study on Niraparib as First Line Maintenance for Newly Diagnosed Advanced Ovarian Cancer
05/03/2022
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib as first-line maintenance therapy, using real-world data.
Jinan Liu, MD, PhD, evaluated...
05/03/2022
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Use of PARP Inhibitor for First-line Maintenance in Newly Diagnosed Ovarian Cancer
05/02/2022
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the use of first-line maintenance therapies among patients with ovarian cancer and examines predictors of first-line poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor maintenance therapy use.
Jinan Liu, MD, PhD describes the...
05/02/2022
Journal of Clinical Pathways
Sarah Temkin, MD
Videos
Survey Aims to Inform Quality Improvement Initiatives in Ovarian Cancer Care Programs
11/01/2021
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a national survey of ovarian cancer care programs in the United States, identifying the needs of patients and informing quality improvement initiatives for these programs.
Sarah Temkin, MD, discusses a...
11/01/2021
Journal of Clinical Pathways
Jinan Liu, MD, PhD
Videos
Real-World Maintenance Therapy Use in Newly Diagnosed Ovarian Cancer
07/24/2021
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.
Jinan Liu, MD, discusses results...
07/24/2021
Journal of Clinical Pathways
Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
Videos
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
04/21/2021
04/21/2021
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
04/24/2025
Lalan Wilfong, MD
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
04/24/2025
Journal of Clinical Pathways
Videos
Confronting Intersectional Stigmas Across the Cancer Care Continuum
04/24/2025
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH,...
04/24/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Strengthening Pathway-Driven Care Through Payer Collaboration
04/23/2025
Gordon Kuntz; Lalan Wilfong, MD
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology...
04/23/2025
Journal of Clinical Pathways
Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
Hafron Headshot
Videos
Developing a National Pathway Framework for Prostate Cancer: Insights from Solaris Health
04/17/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
04/17/2025
Journal of Clinical Pathways
Adam Brufsky, MD
Interview
The Overall Cost-Effectiveness of Adjuvant Ribociclib in ER+ Early Breast Cancer
04/15/2025
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses...
04/15/2025
Journal of Clinical Pathways
Figlin
Videos
Durable Responses With Belzutifan Plus Cabozantinib in Advanced RCC: Updated Findings From LITESPARK-003
04/15/2025
Robert A. Figlin, MD
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert...
04/15/2025
Journal of Clinical Pathways
Speicher headshot
Videos
Building Smarter Pathways: How AI Can Support Precision Oncology Within a Regulatory Framework
04/11/2025
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights...
04/11/2025
Journal of Clinical Pathways
Sahana Somasegar
Interview
Rethinking Immunotherapy: A Case for Personalization in Advanced Endometrial Cancer
04/11/2025
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a...
04/11/2025
Journal of Clinical Pathways
Videos
EV-302 Follow-Up Reinforces Shift in Frontline Urothelial Cancer Pathways
04/10/2025
Thomas Powles, MBBS, MD
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles...
04/10/2025
Journal of Clinical Pathways

Newsfeed

News
Integrated Clinical Pathway Dashboard Enhances Germline Testing in Patients With Ovarian Cancer
03/19/2024

Brandon Twyford

Brandon Twyford
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...
Efforts to streamline and...
03/19/2024
Journal of Clinical Pathways
News
The Cost-Effectiveness of Prevention Strategies for Individuals Who Carry CSGs for Ovarian Cancer and Breast Cancer
03/18/2024

Grace Taylor

Grace Taylor
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.
Ranjit Manchada, PhD, and...
03/18/2024
Journal of Clinical Pathways
News
Individualized Starting Dose of Niraparib in Ovarian Cancer Reduces Hematologic Adverse Event Costs
03/18/2024

Brandon Twyford

Brandon Twyford
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.
A recent study examined the...
03/18/2024
Journal of Clinical Pathways
News
AI Machine Learning Models Accurately Predict Ovarian Cancer Recurrence and Platinum Sensitivity
03/18/2024
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.
Artificial intelligence machine...
03/18/2024
Journal of Clinical Pathways
Conference Coverage
Upifitamab Rilsodoti Did Not Improve Response Rate for Patients With Previously Treated Platinum-Resistant Ovarian Cancer
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
News
Safety and Efficacy Analysis of Lurbinectedin in Patients With Advanced Ovarian Tumors
01/16/2024
Emry Lloyd
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.
An analysis conducted by...
01/16/2024
Journal of Clinical Pathways
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
Stephanie Holland
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
News
Minimally Invasive Surgery vs Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
08/17/2022
Yvette C. Terrie, BS Pharm, RPh
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery with minimally invasive surgery may be a safe and effective choice for interval debunking surgery after neo-adjuvant chemotherapy among patients with advanced ovarian cancer.
Complete cytoreductive surgery...
08/17/2022
Journal of Clinical Pathways
News
Anti-mesothelin CAR-T Immunotherapy Could be Effective in Ovarian Cancer
08/16/2022
Yvette C. Terrie, BS Pharm, RPh
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study revealed the efficacy of the antimesothelin treatment strategy in ovarian cancer and provided preliminary data for the expansion of additional clinical trials.
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Real-World Management of Mucinous Ovarian Cancer
08/11/2022
Yvette C. Terrie, BS Pharm, RPh
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram designed to predict overall survival in patients with mucinous ovarian cancer (MOC) may have valuable significant guidance for the clinical diagnosis and management of patients with MOC for clinical evaluation.
Construction of a nomogram...
08/11/2022
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Study Links Breast Cancer Screening Rates to Social Determinants and Access to Mammography Services
04/11/2025
Hannah Musick
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that...
04/11/2025
Journal of Clinical Pathways
News
New Risk Model Enhances Prognostic Precision in Mantle Cell Lymphoma
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Survival in Mantle Cell Lymphoma Improves With Shifts in Treatment Patterns
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
Predicting HER2 Expression in Gastric Cancer With a Deep Learning Model
04/07/2025
Juliet Gallagher
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in...
04/07/2025
Journal of Clinical Pathways
News
Financial Strain Persists for Patients With Cancer Despite Support Referrals
04/04/2025
Grace Taylor, MS, MA
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support,...
04/04/2025
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Opportunistic Salpingectomy for Ovarian Cancer Prevention
02/24/2022
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic salpingectomy at the time of elective cholecystectomy is not a cost-effective strategy to prevent ovarian cancer among average risk women.
True or False: Opportunistic...
02/24/2022
Journal of Clinical Pathways
Quiz
Quiz: PARP Inhibitors in Patients With Epithelial Ovarian Cancer
12/14/2021
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a study assessing patients’ and oncologists’ preferences for second-line PARP inhibitor maintenance in epithelial ovarian cancer suggest that the PFS gains are worth the toxicity risk.
True or False: Findings from a...
12/14/2021
Journal of Clinical Pathways
Quiz
Quiz: Differences Between Available PARP Inhibitors for Ovarian Cancer
12/08/2021
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are differences between available PARP inhibitors in the risk of experiencing a clinical event of interest, likelihood of dose modifications, ability to receive continuous therapy, health care resource utilization, and...
True or False: There are...
12/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Olaparib Maintenance for Ovarian Cancer
10/06/2021
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
True or False: Olaparib...
10/06/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Olaparib vs Niraparib for the Treatment of Ovarian Cancer
09/24/2021
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
True or False: Olaparib is more...
09/24/2021
Journal of Clinical Pathways
Quiz
Quiz: First-Line Maintenance Therapy for Ovarian Cancer
08/05/2021
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line maintenance therapy use for ovarian cancer has decreased over time, particularly among patients with biomarker guidance.
True or False: First-line...
08/05/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of VTE Prophylaxis for Ovarian Cancer
07/27/2021
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous thromboembolism prophylaxis with direct oral anticoagulants during neoadjuvant chemotherapy for ovarian cancer is more costly but more effective than no therapy.
True or False: Venous...
07/27/2021
Journal of Clinical Pathways
Quiz
Quiz: Is First-Line Niraparib Maintenance Cost-Effective for Patients With Advanced Ovarian Cancer?
04/16/2021
04/16/2021
Journal of Clinical Pathways
Quiz
Quiz: How Can We Optimize Genetic Testing for Breast and Ovarian Cancer?
03/17/2021
03/17/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP March/April 2025

Current Issue

April 2025
Volume 11
Issue 2
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use